BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 19363212)

  • 1. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.
    Huang DT; Angus DC; Kellum JA; Pugh NA; Weissfeld LA; Struck J; Delude RL; Rosengart MR; Yealy DM
    Chest; 2009 Sep; 136(3):823-831. PubMed ID: 19363212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
    Courtais C; Kuster N; Dupuy AM; Folschveiller M; Jreige R; Bargnoux AS; Guiot J; Lefebvre S; Cristol JP; Sebbane M
    Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.
    Bello S; Lasierra AB; Mincholé E; Fandos S; Ruiz MA; Vera E; de Pablo F; Ferrer M; Menendez R; Torres A
    Eur Respir J; 2012 May; 39(5):1144-55. PubMed ID: 22075489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.
    Gordo-Remartínez S; Calderón-Moreno M; Fernández-Herranz J; Castuera-Gil A; Gallego-Alonso-Colmenares M; Puertas-López C; Nuevo-González JA; Sánchez-Sendín D; García-Gámiz M; Sevillano-Fernández JA; Álvarez-Sala LA; Andueza-Lillo JA; de Miguel-Yanes JM
    PLoS One; 2015; 10(6):e0125212. PubMed ID: 26030588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.
    Suberviola B; Castellanos-Ortega A; Llorca J; Ortiz F; Iglesias D; Prieto B
    Swiss Med Wkly; 2012; 142():w13542. PubMed ID: 22430899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia.
    Huang DT; Weissfeld LA; Kellum JA; Yealy DM; Kong L; Martino M; Angus DC;
    Ann Emerg Med; 2008 Jul; 52(1):48-58.e2. PubMed ID: 18342993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
    Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
    Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin.
    Bello S; Fandos S; Lasierra AB; Mincholé E; Panadero C; Simon AL; Gavin O; De Pablo F; Menendez R; Torres A
    Respir Med; 2015 Sep; 109(9):1193-206. PubMed ID: 26205553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].
    Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B
    Crit Care; 2006; 10(3):R96. PubMed ID: 16805922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midregional proadrenomedullin for prognosis in community-acquired pneumonia: a systematic review.
    Cavallazzi R; El-Kersh K; Abu-Atherah E; Singh S; Loke YK; Wiemken T; Ramirez J
    Respir Med; 2014 Nov; 108(11):1569-80. PubMed ID: 25448309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
    España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
    J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
    Pereira JM; Azevedo A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
    Rev Port Pneumol (2006); 2016; 22(6):308-314. PubMed ID: 27160747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis.
    Bernal-Morell E; García-Villalba E; Vera MDC; Medina B; Martinez M; Callejo V; Valero S; Cinesi C; Piñera P; Alcaraz A; Marin I; Muñoz A; Cano A
    J Infect; 2018 Mar; 76(3):249-257. PubMed ID: 29246637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.
    Legramante JM; Mastropasqua M; Susi B; Porzio O; Mazza M; Miranda Agrippino G; D Agostini C; Brandi A; Giovagnoli G; Di Lecce VN; Bernardini S; Minieri M
    PLoS One; 2017; 12(11):e0187702. PubMed ID: 29161297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis.
    Liu D; Xie L; Zhao H; Liu X; Cao J
    BMC Infect Dis; 2016 May; 16():232. PubMed ID: 27230573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index.
    Masiá M; Gutiérrez F; Shum C; Padilla S; Navarro JC; Flores E; Hernández I
    Chest; 2005 Oct; 128(4):2223-9. PubMed ID: 16236878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department].
    Julián-Jiménez A; Timón Zapata J; Laserna Mendieta EJ; Sicilia-Bravo I; Palomo-de Los Reyes MJ; Cabezas-Martínez A; Laín-Terés N; Estebaran-Martín J; Lozano-Ancín A; Cuena-Boy R
    Enferm Infecc Microbiol Clin; 2014 Apr; 32(4):225-35. PubMed ID: 24182623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of procalcitonin in community-acquired pneumonia.
    Schuetz P; Suter-Widmer I; Chaudri A; Christ-Crain M; Zimmerli W; Mueller B;
    Eur Respir J; 2011 Feb; 37(2):384-92. PubMed ID: 20595156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity and Specificity of Soluble Triggering Receptor Expressed on Myeloid Cells-1, Midregional Proatrial Natriuretic Peptide and Midregional Proadrenomedullin for Distinguishing Etiology and to Assess Severity in Community-Acquired Pneumonia.
    Esposito S; Di Gangi M; Cardinale F; Baraldi E; Corsini I; Da Dalt L; Tovo PA; Correra A; Villani A; Sacco O; Tenero L; Dones P; Gambino M; Zampiero A; Principi N;
    PLoS One; 2016; 11(11):e0163262. PubMed ID: 27846213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proadrenomedullin improves Risk of Early Admission to ICU score for predicting early severe community-acquired pneumonia.
    Renaud B; Schuetz P; Claessens YE; Labarère J; Albrich W; Mueller B
    Chest; 2012 Dec; 142(6):1447-1454. PubMed ID: 22661450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.